302806-41-3Relevant academic research and scientific papers
Real-time in situ monitoring via europium emission of the photo-release of antitumor cisplatin from a Eu-Pt complex
Li, Hongguang,Lan, Rongfeng,Chan, Chi-Fai,Jiang, Lijun,Dai, Lixiong,Kwong, Daniel W. J.,Lam, Michael Hon-Wah,Wong, Ka-Leung
, p. 14022 - 14025 (2015)
A water-soluble light-responsive antitumor agent, PtEuL, based on a cisplatin-linked europium-cyclen complex has been synthesized and evaluated for controlled cisplatin release by linear/two-photon excitation in vitro with concomitant turn-on and long-liv
lanthanide toolbox for multi-modal, non-invasive tumor specific theranostic prodrugs
-
Paragraph 0142-0144, (2018/04/13)
The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin αvβ3.
Anticancer activity of self-assembled molecular rectangles via arene-ruthenium acceptors and a new unsymmetrical amide ligand
Mishra, Anurag,Jung, Hyunji,Park, Jeong Woo,Kim, Hong Kyeung,Kim, Hyunuk,Stang, Peter J.,Chi, Ki-Whan
experimental part, p. 3519 - 3526 (2012/06/16)
Two new and large molecular rectangles 4 and 5 were synthesized from two different arene-ruthenium [Ru2(μ-η4-C 2O4)(MeOH)2(η6-p-Pr iC6H4Me)2][O3SCF 3]2 (2) and [Ru2(p-cymene)2(donq) (OH2)2][O3SCF3]2 (donq = 5,8-dioxydo-1,4-naphthaquinonato) (3) acceptors and a new unsymmetrical N-(4-(pyridin-4-ylethynyl)phenyl) isonicotinamide (1) donor ligand. X-ray crystallography of 4 confirmed a molecular rectangle. The 1H NMR spectra of both rectangles 4 and 5 showed a mixture of two structural, head-to-tail (HTT) and head-to-head (HTH), type isomers in a 1:1 ratio. The cytotoxicities of both rectangles have been established against Colo320 (colorectal cancer), A549 (lung cancer), MCF-7 (breast cancer), and H1299 (lung cancer) human cancer cell lines. The cytotoxicity of rectangle 5 was found to be considerably stronger against all cancer cell lines than that of the reference drug cisplatin.
Pyridinium cationic-dimer antimalarials, unlike chloroquine, act selectively between the schizont stage and the ring stage of Plasmodium falciparum
Yoshikawa, Mai,Motoshima, Kazunori,Fujimoto, Kanji,Tai, Akihiro,Kakuta, Hiroki,Sasaki, Kenji
, p. 6027 - 6033 (2008/12/22)
Malaria is a leading cause of death in developing countries, and the emergence of strains resistant to the main therapeutic agent, chloroquine, has become a serious problem. We have developed cationic-dimer type antimalarials, MAP-610 and PMAP-H10, which
